GlassScriptPhysician profile
Michael John Renner
NPI 1386602662
$7,870.14
in general payments reported to CMS, 2019-2025
39 companies · $996 in 2025
The $996 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $507 · 2020: $1,140 · 2021: $1,415 · 2022: $1,402 · 2023: $1,203 · 2024: $1,208 · 2025: $996.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,407.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,705.95 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $709.43 | 2019-2025 | Farxiga, Airsupra |
| Otsuka America Pharmaceutical, INC. | $546.14 | 2019-2025 | Rexulti, Abilify Maintena |
| Lilly USA, LLC | $508.45 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $486.05 | 2019-2025 | Jardiance, Synjardy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $442.31 | 2022-2025 | Caplyta |
| Abbvie INC. | $412.28 | 2021-2025 | |
| Amgen INC. | $383.62 | 2019-2025 | Evenity, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $363.31 | 2022-2024 | |
| Lundbeck LLC | $299.23 | 2022-2025 | Rexulti |
| Pfizer INC. | $245.07 | 2020-2025 | |
| Amarin Pharma, INC. | $217.60 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $208.13 | 2020-2022 | |
| Glaxosmithkline, LLC. | $204.30 | 2020-2024 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $141.10 | 2019-2020 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Renner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.